Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hib-DTP vaccine - sanofi pasteur

Next Previous
Drug Profile

Hib-DTP vaccine - sanofi pasteur

Alternative Names: Act-HIB DTP; ProHIBIT-DPT; TETRAct-HIB

Latest Information Update: 25 Mar 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Tetanus

Most Recent Events

  • 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top